FDA approves 2nd rare bone disease treatment

Ipsen’s Sohonos had been the only FDA-approved treatment for fibrodysplasia ossificans progressiva, an ultra-rare disease affecting roughly 900 people worldwide. That changed Aug. 19 when the agency approved Regeneron’s IV infusion. With Pasatru’s approval, FOP moves from a one-drug market to one in which physicians and patients have a choice. The two drugs work differently. […] The post FDA…